deltatrials
Terminated PHASE1 NCT00125411

Study of Satraplatin (JM-216) in Combination With Docetaxel

Phase I Study of the Oral Platinum Agent Satraplatin (JM-216) in Combination With Docetaxel in Treatment of Advanced Malignancies

Sponsor: Agennix

Conditions Tumors
Interventions satraplatin and docetaxel
Updated 6 times since 2017 Last updated: Mar 22, 2012 Started: Mar 31, 2007 Primary completion: Feb 28, 2009 Completion: Feb 28, 2009

Listed as NCT00125411, this PHASE1 trial focuses on Tumors and remains terminated or withdrawn. Sponsored by Agennix, it has been updated 6 times since 2007, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE1

  4. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE1

  5. Feb 2017 — Jun 2018 [monthly]

    Terminated PHASE1

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE1

    First recorded

Mar 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Agennix
Data source: Agennix

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Madison, United States